Contact Us
Drug Search Results
More Filters [+]

Ozenoxacin

Alternative Names: ozenoxacin, gf-001001-00, gf 001001 00, gf00100100, xepi
Latest Update: 2024-08-20
Latest Update Note: Clinical Trial Update

Product Description

Ozenoxacin, a novel non-fluorinated topical quinolone antimicrobial, has demonstrated efficacy in impetigo. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30686133/)

Mechanisms of Action: DNA Replication Inhibitor,DNA Gyrase Inhibitor,TOP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Belgium | Canada | Germany | India | Ireland | Italy | Japan | Poland | Portugal | Spain | Sweden | United Arab Emirates | United States

Approved Indications: Impetigo

Known Adverse Events: Dermatitis | Dermatitis, Seborrheic | Rosacea | Pregnancy Outcomes | Pregnancy, Prolonged

Company: Ferrer Internacional
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ozenoxacin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Impetigo

Phase 2: Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
JapicCTI-194643

P3

Unknown

Impetigo

2019-06-30

2014-000228-52

P3

Completed

Impetigo

2015-05-30

P-110881-01

P3

Completed

Impetigo

2015-05-01

2012-000746-36

P1

Completed

Impetigo

2013-02-09

Recent News Events

Date

Type

Title

09/07/2023

News Article

 The projection for the Wind Power Crane market analysis from 2023 to 2030 and market size estimated to be 8.3% CAGR

09/01/2023

News Article

 Impetigo Drug Market Identifying Emerging Market Trends and Opportunities in 2023- Destiny Pharma Ltd, Foamix Pharmaceuticals Ltd, Fujifilm Holdings Corporation, Laboratories Ojer Pharma SL

11/28/2022

News Article

 BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022

10/18/2022

News Article

 Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions